Insider Trading History of Redmile Biopharma Investments Iii, L.p.

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Redmile Biopharma Investments Iii, L.p. since 2021. This trader's CIK number is 1838746. At the time of last reporting, Redmile Biopharma Investments Iii, L.p. was the Officer of Attovia Therapeutics, Inc.. (stock ticker symbol ATTO). Also see all insider trading activities at Attovia Therapeutics, Inc..

Note that in the past Redmile Biopharma Investments III, L.P. also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Entrada Therapeutics, Inc. (TRDA) by Redmile Biopharma Investments Iii, L.p.

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2021 TRDA 1,000,000 $20,000,000 0 $0 0 $0

Yearly summary of insider trading at Attovia Therapeutics, Inc. (ATTO) by Redmile Biopharma Investments Iii, L.p.

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2026 ATTO 600,000 $10,200,000 0 $0 0 $0


Insider trading activities at 2 companies by Redmile Biopharma Investments Iii, L.p.:

1. Entrada Therapeutics, Inc. (TRDA)

2. Attovia Therapeutics, Inc. (ATTO)

Table 1. Insider trading of Entrada Therapeutics, Inc. (TRDA) by Redmile Biopharma Investments Iii, L.p.

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2021-11-02 TRDA Buy 1,000,000 20.00 20,000,000

Table 2. Insider trading of Attovia Therapeutics, Inc. (ATTO) by Redmile Biopharma Investments Iii, L.p.

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2026-08-06 ATTO Buy 600,000 17.00 10,200,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Redmile Biopharma Investments Iii, L.p. (Officer of Attovia Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.